Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy

Bibliography

• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505(7484):495-501
   PubMed Web of Science ®Google Scholar
• Wang X, Haswell JR, Roberts CW. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer-mechanisms and potential therapeutic insights. Clin Cancer Res 2014;20(1):21-7
   PubMed Web of Science ®Google Scholar
• Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394(6689):203-6
   PubMed Web of Science ®Google Scholar
• Huether R, Dong L, Chen X, et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014;5:3630
   PubMed Web of Science ®Google Scholar
• Sankar S, Lessnick SL. Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet 2011;204(7):351-65
   PubMed Web of Science ®Google Scholar
• Kovar H. Downstream EWS/FLI1 - upstream Ewing´s sarcoma. Genome Med 2010;2(1):8
   PubMedGoogle Scholar
• Uren A, Toretsky JA. Ewing’s sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005;1(4):521-8
   PubMedGoogle Scholar
• Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 2008;30(6):425-30
   PubMed Web of Science ®Google Scholar
• Bernstein M, Kovar H, Paulussen M, et al. Ewing’s sarcoma family of tumors: current management. Oncologist 2006;11(5):503-19
   PubMed Web of Science ®Google Scholar
• Potratz J, Dirksen U, Jurgens H, et al. Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 2012;29(1):1-11
   PubMed Web of Science ®Google Scholar
• Longhi A, Ferrari S, Tamburini A, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer 2012;118(20):5050-9
   PubMed Web of Science ®Google Scholar
• Parks R, Rasch EK, Mansky PJ, et al. Differences in activities of daily living performance between long-term pediatric sarcoma survivors and a matched comparison group on standardized testing. Pediatr Blood Cancer 2009;53(4):622-8
   PubMed Web of Science ®Google Scholar
• Aksnes LH, Bauer HC, Dahl AA, et al. Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. Pediatr Blood Cancer 2009;53(1):84-9
   PubMed Web of Science ®Google Scholar
• Youn P, Milano MT, Constine LS, et al. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer 2014;120(15):2334-42
   PubMed Web of Science ®Google Scholar
• Kovar H, Aryee D, Zoubek A. The Ewing family of tumors and the search for the Achilles’ heel. Curr Opin Oncol 1999;11(4):275-84
   PubMedGoogle Scholar
• Uren A, Merchant MS, Sun CJ, et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene 2003;22(15):2334-42
   PubMed Web of Science ®Google Scholar
• Bozzi F, Tamborini E, Negri T, et al. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 2007;109(8):1638-45
   PubMedGoogle Scholar
• Ikeda AK, Judelson DR, Federman N, et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther 2010;9(3):653-60
   PubMed Web of Science ®Google Scholar
• Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10(2):751-61
   PubMed Web of Science ®Google Scholar
• Chao J, Budd GT, Chu P, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 2010;30(2):547-52
   PubMed Web of Science ®Google Scholar
• Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 2008;50(2):254-8
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009;27(19):3148-53
   PubMed Web of Science ®Google Scholar
• Wang Y, Mandal D, Wang S, et al. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer 2010;116(16):3892-902
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Nordenberg J, Beery E, et al. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol 2007;29(2):126-31
   PubMedGoogle Scholar
• Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272(49):30822-7
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing’s sarcoma in athymic mice. Cancer Res 1998;58(18):4127-31
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20(4):419-27
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65(9):3868-76
   PubMed Web of Science ®Google Scholar
• Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24(16):7275-83
   PubMed Web of Science ®Google Scholar
• Kang HG, Jenabi JM, Liu XF, et al. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther 2010;9(5):1396-407
   PubMed Web of Science ®Google Scholar
• Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2012;30(3):256-62
   PubMed Web of Science ®Google Scholar
• Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012;30(15):1849-56
   PubMed Web of Science ®Google Scholar
• Weigel B, Malempati S, Reid JM, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2014;61(3):452-6
   PubMed Web of Science ®Google Scholar
• Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29(34):4541-7
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013;14(4):371-82
   PubMed Web of Science ®Google Scholar
• Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 2012;18(9):2625-31
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69(19):7662-71
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Chung YA, Moody G, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing’s and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337(3):644-54
   PubMed Web of Science ®Google Scholar
• Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12(11 Pt 1):3532-40
   PubMed Web of Science ®Google Scholar
• Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 2012;72(7):1608-13
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483(7391):570-5
   PubMed Web of Science ®Google Scholar
• Prasad SC, Thraves PJ, Bhatia KG, et al. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing’s sarcoma cells. Cancer Res 1990;50(1):38-43
   PubMed Web of Science ®Google Scholar
• Norris RE, Adamson PC, Nguyen VT, et al. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer 2014;61(1):145-50
   PubMed Web of Science ®Google Scholar
• Lee HJ, Yoon C, Schmidt B, et al. Combining PARP-1 inhibition and radiation in ewing sarcoma results in lethal DNA damage. Mol Cancer Ther 2013;12(11):2591-600
   PubMed Web of Science ®Google Scholar
• Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011;71(17):5626-34
   PubMed Web of Science ®Google Scholar
• Soldatenkov VA, Albor A, Patel BK, et al. Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 1999;18(27):3954-62
   PubMed Web of Science ®Google Scholar
• Soldatenkov VA, Trofimova IN, Rouzaut A, et al. Differential regulation of the response to DNA damage in Ewing’s sarcoma cells by ETS1 and EWS/FLI-1. Oncogene 2002;21(18):2890-5
   PubMed Web of Science ®Google Scholar
• Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007;4(4):e122
   PubMed Web of Science ®Google Scholar
• DuBois SG, Krailo MD, Lessnick SL, et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52(3):324-7
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Woldemichael GM, Griffin LB, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 2011;103(12):962-78
   PubMed Web of Science ®Google Scholar
• Boro A, Pretre K, Rechfeld F, et al. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing’s sarcoma. Int J Cancer 2012;131(9):2153-64
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13(2):145-53
   PubMed Web of Science ®Google Scholar
• Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011;80:437-71
   PubMed Web of Science ®Google Scholar
• Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7(4):429-37
   PubMedGoogle Scholar
• Bilke S, Schwentner R, Yang F, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013;23(11):1797-809
   PubMed Web of Science ®Google Scholar
• Kim S, Denny CT, Wisdom R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 2006;26(7):2467-78
   PubMed Web of Science ®Google Scholar
• Patel M, Simon JM, Iglesia MD, et al. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res 2012;22(2):259-70
   PubMed Web of Science ®Google Scholar
• Kovar H. Dr. Jekyll and Mr. Hyde, the two faces of the FUS/EWS/TAF15 protein family. Sarcoma 2011;2011:837474
   PubMedGoogle Scholar
• Ng KP, Potikyan G, Savene RO, et al. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc Natl Acad Sci USA 2007;104(2):479-84
   PubMed Web of Science ®Google Scholar
• Hegyi H, Buday L, Tompa P. Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. PLoS Comput Biol 2009;5(10):e1000552
   PubMed Web of Science ®Google Scholar
• Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7(6):673-9
   PubMed Web of Science ®Google Scholar
• Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing’s sarcoma. PLoS One 2009;4(4):e5415
   PubMed Web of Science ®Google Scholar
• von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One 2011;6(4):e19305
   PubMed Web of Science ®Google Scholar
• Riggi N, Suva ML, De Vito C, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010;24(9):916-32
   PubMed Web of Science ®Google Scholar
• Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68(7):2176-85
   PubMed Web of Science ®Google Scholar
• Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2007;7(2):250-6
   PubMed Web of Science ®Google Scholar
• Kovar H. Context matters: the hen or egg problem in Ewing’s sarcoma. Semin Cancer Biol 2005;15(3):189-96
   PubMed Web of Science ®Google Scholar
• Takashima Y, Era T, Nakao K, et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007;129(7):1377-88
   PubMed Web of Science ®Google Scholar
• Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466(7308):829-34
   PubMed Web of Science ®Google Scholar
• Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64(22):8213-21
   PubMed Web of Science ®Google Scholar
• France KA, Anderson JL, Park A, et al. Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms. J Biol Chem 2011;286(26):22750-7
   PubMed Web of Science ®Google Scholar
• Lin PP, Wang Y, Lozano G. Mesenchymal stem cells and the origin of Ewing’s sarcoma. Sarcoma 2011;2011:276463
   PubMedGoogle Scholar
• Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010;36(4):286-97
   PubMed Web of Science ®Google Scholar
• Lessnick SL, Braun BS, Denny CT, et al. Multiple domains mediate transformation by the Ewing’s sarcoma EWS/FLI-1 fusion gene. Oncogene 1995;10(3):423-31
   PubMed Web of Science ®Google Scholar
• Potikyan G, France KA, Carlson MR, et al. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing’s family tumors. Lab Invest 2008;88(12):1291-302
   PubMed Web of Science ®Google Scholar
• Gonzalez I, Vicent S, De Alava E, et al. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med 2007;85(9):1015-29
   PubMed Web of Science ®Google Scholar
• Torchia EC, Boyd K, Rehg JE, et al. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol 2007;27(22):7918-34
   PubMed Web of Science ®Google Scholar
• Lin PP, Pandey MK, Jin F, et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008;68(21):8968-75
   PubMed Web of Science ®Google Scholar
• Leacock SW, Basse AN, Chandler GL, et al. A zebrafish transgenic model of Ewing’s sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Dis Models Mech 2012;5(1):95-106
   PubMed Web of Science ®Google Scholar
• Tanaka M, Yamazaki Y, Kanno Y, et al. Ewing’s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. J Clin Invest 2014;124(7):3061-74
   PubMed Web of Science ®Google Scholar
• Coles EG, Lawlor ER, Bronner-Fraser M. EWS-FLI1 causes neuroepithelial defects and abrogates emigration of neural crest stem cells. Stem Cells 2008;26(9):2237-44
   PubMed Web of Science ®Google Scholar
• Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007;128(4):635-8
   PubMed Web of Science ®Google Scholar
• Braunreiter CL, Hancock JD, Coffin CM, et al. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing’s sarcoma. Cell Cycle 2006;5(23):2753-9
   PubMed Web of Science ®Google Scholar
• Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. ExpCell Res 2003;290(2):414-19
   PubMed Web of Science ®Google Scholar
• Thompson AD, Teitell MA, Arvand A, et al. Divergent Ewing’s sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 1999;18(40):5506-13
   PubMed Web of Science ®Google Scholar
• Gangwal K, Lessnick SL. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI’s treasure. Cell Cycle 2008;7(20):3127-32
   PubMed Web of Science ®Google Scholar
• Guillon N, Tirode F, Boeva V, et al. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009;4(3):e4932
   Web of Science ®Google Scholar
• Bilke S, Schwentner R, Yang F, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013;23(11):1797-809
   PubMed Web of Science ®Google Scholar
• Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 2009;106(13):5324-9
   PubMed Web of Science ®Google Scholar
• Wei GH, Badis G, Berger MF, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010;29(13):2147-60
   PubMed Web of Science ®Google Scholar
• Gangwal K, Close D, Enriquez CA, et al. Emergent properties of EWS/FLI regulation via GGAA microsatellites in Ewing’s sarcoma. Genes Cancer 2010;1(2):177-87
   PubMedGoogle Scholar
• Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS- FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14(5):3230-41
   PubMed Web of Science ®Google Scholar
• May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993;90(12):5752-6
   PubMed Web of Science ®Google Scholar
• Gangwal K, Sankar S, Hollenhorst PC, et al. Microsatellites as EWS/FLI response elements in Ewing’s sarcoma. Proc Natl Acad Sci USA 2008;105(29):10149-54
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Fujimura Y, Zou JP, et al. Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene 2004;23(42):7087-94
   PubMed Web of Science ®Google Scholar
• Sankar S, Bell R, Stephens B, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 2013;32(42):5089-100
   PubMed Web of Science ®Google Scholar
• Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999;23(2):222-7
   PubMed Web of Science ®Google Scholar
• Kinsey M, Smith R, Iyer AK, et al. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing’s sarcoma. Cancer Res 2009;69(23):9047-55
   PubMed Web of Science ®Google Scholar
• Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One 2008;3(4):e1965
   Web of Science ®Google Scholar
• Wiles ET, Lui-Sargent B, Bell R, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. PLoS One 2013;8(3):e59369
   Web of Science ®Google Scholar
• Zhou Z, Yu L, Kleinerman ES. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer 2014;120(4):579-88
   PubMed Web of Science ®Google Scholar
• Niedan S, Kauer M, Aryee DN, et al. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing’s sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3(7):e2634
   PubMed Web of Science ®Google Scholar
• Martins AS, Ordonez JL, Amaral AT, et al. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis. PLoS One 2011;6(5):e19846
   Web of Science ®Google Scholar
• McKinsey EL, Parrish JK, Irwin AE, et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011;30(49):4910-20
   PubMed Web of Science ®Google Scholar
• Huang HJ, Angelo LS, Rodon J, et al. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing’s sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 2011;6(10):e26060
   Web of Science ®Google Scholar
• Zhang W, Zong CS, Hermanto U, et al. RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol Cell Biol 2006;26(2):413-24
   PubMed Web of Science ®Google Scholar
• Behjati S, Basu BP, Wallace R, et al. STAT3 regulates proliferation and immunogenicity of the ewing family of tumors in vitro. Sarcoma 2012;2012:987239
   PubMedGoogle Scholar
• Lai R, Navid F, Rodriguez-Galindo C, et al. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol 2006;208(5):624-32
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56(20):4570-4
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;56(4):595-603
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(6):1190-7
   PubMed Web of Science ®Google Scholar
• Zheng H, Shen H, Oprea I, et al. Beta-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing’s sarcoma. Proc Natl Acad Sci USA 2012;109(50):20620-5
   PubMed Web of Science ®Google Scholar
• Subbiah V, Naing A, Brown RE, et al. Targeted morphoproteomic profiling of Ewing’s sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 2011;6(4):e18424
   PubMed Web of Science ®Google Scholar
• Garofalo C, Mancarella C, Grilli A, et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing’s sarcoma. Mol Endocrinol 2012;26(9):1603-16
   PubMedGoogle Scholar
• Erkizan HV, Scher LJ, Gamble SE, et al. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle 2011;10(19):3397-408
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Erkizan V, Levenson A, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 2006;66(11):5574-81
   PubMed Web of Science ®Google Scholar
• Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 2009;15(7):750-6
   PubMed Web of Science ®Google Scholar
• Barber-Rotenberg JS, Selvanathan SP, Kong Y, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012;3(2):172-82
   PubMedGoogle Scholar
• Hong SH, Youbi SE, Hong SP, et al. Pharmacokinetic modeling optimizes inhibition of the ’undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget 2014;5(2):338-50
   PubMedGoogle Scholar
• Rahim S, Beauchamp EM, Kong Y, et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 2011;6(4):e19343
   Web of Science ®Google Scholar
• Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering rna inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res 2005;65(19):8984-92
   PubMed Web of Science ®Google Scholar
• Alhaddad A, Adam MP, Botsoa J, et al. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 2011;7(21):3087-95
   PubMed Web of Science ®Google Scholar
• Alhaddad A, Durieu C, Dantelle G, et al. Influence of the internalization pathway on the efficacy of siRNA delivery by cationic fluorescent nanodiamonds in the Ewing sarcoma cell model. PLoS One 2012;7(12):e52207
   Web of Science ®Google Scholar
• Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 2006;23(5):892-900
   PubMed Web of Science ®Google Scholar
• Takigami I, Ohno T, Kitade Y, et al. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer 2011;128(1):216-26
   PubMed Web of Science ®Google Scholar
• Sengupta A, Rahman M, Mateo-Lozano S, et al. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing’s sarcoma. Int J Oncol 2013;43(3):803-12
   PubMed Web of Science ®Google Scholar
• Bachmaier R, Aryee DN, Jug G, et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing’s sarcoma. Oncogene 2009;28(9):1280-4
   PubMed Web of Science ®Google Scholar
• Klevernic IV, Morton S, Davis RJ, et al. Phosphorylation of Ewing’s sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 2009;418(3):625-34
   PubMedGoogle Scholar
• Schlottmann S, Erkizan HV, Barber-Rotenberg JS, et al. Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Front Oncol 2012;2:107
   Google Scholar
• Alholle A, Brini AT, Gharanei S, et al. Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. Epigenetics 2013;8(11):1198-204
   PubMed Web of Science ®Google Scholar
• Nestheide S, Bridge JA, Barnes M, et al. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma. Pediatr Blood Cancer 2013;60(9):1437-46
   PubMed Web of Science ®Google Scholar
• Patel N, Black J, Chen X, et al. DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma 2012;2012:498472
   PubMedGoogle Scholar
• Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell 2013;155(4):934-47
   PubMed Web of Science ®Google Scholar
• Luo W, Gangwal K, Sankar S, et al. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing’s sarcoma oncogenesis and therapeutic resistance. Oncogene 2009;28(46):4126-32
   PubMed Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339(6121):823-6
   PubMed Web of Science ®Google Scholar
• Christensen L, Joo J, Lee S, et al. FOXM1 is an oncogenic mediator in Ewing Sarcoma. PLoS One 2013;8(1):e54556
   PubMed Web of Science ®Google Scholar
• Yang L, Hu HM, Zielinska-Kwiatkowska A, et al. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing’s sarcoma cells. Biochem Biophys Res Commun 2010;402(1):129-34
   PubMed Web of Science ®Google Scholar
• Beauchamp E, Bulut G, Abaan O, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284(14):9074-82
   PubMed Web of Science ®Google Scholar
• De Vito C, Riggi N, Suva ML, et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewing’s sarcoma development. PLoS One 2011;6(8):e23592
   Web of Science ®Google Scholar
• Agra N, Cidre F, Garcia-Garcia L, et al. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in ewing sarcoma cells. PLoS One 2013;8(6):e66281
   PubMed Web of Science ®Google Scholar
• Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma. Mol Cancer Res 2006;4(11):851-9
   PubMed Web of Science ®Google Scholar
• Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing’s tumor cells. Oncogene 2008;27(46):6034-43
   PubMed Web of Science ®Google Scholar
• Abaan OD, Levenson A, Khan O, et al. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing’s Sarcoma tumorigenesis. Oncogene 2005;24(16):2715-22
   PubMed Web of Science ®Google Scholar
• Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes Ewing sarcoma growth. Cancer Res 2012;72(17):4494-503
   PubMed Web of Science ®Google Scholar